GSK
NEWS
The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Brii Biosciences is launching to accelerate the development and delivery of breakthrough drugs in China with $260 million in financial backing.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
Prime Minister Theresa May continues to push for growth in the United Kingdom’s pharma sector. Today she called for expanding the role of artificial intelligence in the diagnosis process for cancer.
This weekend GSK unveiled long-term data that showed that one-third of patients treated with Nucala (mepolizumab) experienced no asthma-related exacerbations during the study.
Two years after entering into a licensing relationship Canada-based Zymeworks Inc. and Japanese pharma giant Daiichi Sankyo have entered into a second licensing agreement to expand immuno-oncology research with bispecific antibodies.
Changes continue at the c-suite level of GlaxoSmithKline. This week another high profile executive, Chief Financial Officer Simon Dingemans announced he will retire from GSK in 2019.
You know when an analyst starts an article with, “Gilead’s Q1 financial results were a disaster,” that it requires a closer look.
JOBS
IN THE PRESS